Search research articles
Contact Us
Filters
Showing results (411-420 of 424) with videos related to
Page
of 43
Sort By:
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
December 1, 1991
Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience
E M Hersh, B S Metch, F M Muggia, et al.
Gynecologic Oncology
|
June 1, 1996
Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group
F M Muggia, P Y Liu, D S Alberts, et al.
The New England Journal of Medicine
|
December 3, 1987
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer
S D Williams, D M Stablein, L H Einhorn, et al.
Gynecologic Oncology
|
September 4, 2024
A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus
B Pothuri, Z Sawaged, H C Karpel, et al.
Journal of Liposome Research
|
February 27, 2003
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies
J Szebeni, L Baranyi, S Savay, et al.
Cancer Chemotherapy and Pharmacology
|
May 13, 1999
Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors
R T Koda, A A Garcia, D J Chatterjee, et al.
Seminars in Oncology
|
February 19, 2005
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials
David S Alberts, Franco M Muggia, James Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1997
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation
F M Muggia, J D Hainsworth, S Jeffers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
A L Hamilton, J P Eder, A C Pavlick, et al.
Cancer Treatment Reports
|
July 1, 1976
Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung
J H Edmonson, S W Lagakos, O S Selawry, et al.
Page
of 43
Search research articles
Search
Showing results (411-420 of 424) with videos related to
Sort By:
Page
of 43
Journal of Immunotherapy : Official Journal of the Society for Biological Therapy
|
December 1, 1991
Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience
E M Hersh, B S Metch, F M Muggia, et al.
Gynecologic Oncology
|
June 1, 1996
Intraperitoneal mitoxantrone or floxuridine: effects on time-to-failure and survival in patients with minimal residual ovarian cancer after second-look laparotomy--a randomized phase II study by theSouthwest Oncology Group
F M Muggia, P Y Liu, D S Alberts, et al.
The New England Journal of Medicine
|
December 3, 1987
Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer
S D Williams, D M Stablein, L H Einhorn, et al.
Gynecologic Oncology
|
September 4, 2024
A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus
B Pothuri, Z Sawaged, H C Karpel, et al.
Journal of Liposome Research
|
February 27, 2003
Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies
J Szebeni, L Baranyi, S Savay, et al.
Cancer Chemotherapy and Pharmacology
|
May 13, 1999
Phase I study of AG 331, a novel thymidylate synthase inhibitor, in patients with refractory solid tumors
R T Koda, A A Garcia, D J Chatterjee, et al.
Seminars in Oncology
|
February 19, 2005
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials
David S Alberts, Franco M Muggia, James Carmichael, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 1997
Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation
F M Muggia, J D Hainsworth, S Jeffers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2005
Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle
A L Hamilton, J P Eder, A C Pavlick, et al.
Cancer Treatment Reports
|
July 1, 1976
Cyclophosphamide and CCNU in the treatment of inoperable small cell carcinoma and adenocarcinoma of the lung
J H Edmonson, S W Lagakos, O S Selawry, et al.
Page
of 43